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Abstract
Background
Rapid reliable diagnostics of DNAmutations are highly desirable in research and clinical
assays. Current development in this field goes simultaneously in two directions: 1) high-
throughput methods, and 2) portable assays. Non-enzymatic approaches are attractive for
both types of methods since they would allow rapid and relatively inexpensive detection of
nucleic acids. Modern fluorescence microscopy is having a huge impact on detection of bio-
molecules at previously unachievable resolution. However, no straightforward methods to
detect DNA in a non-enzymatic way using fluorescence microscopy and nucleic acid ana-
logues have been proposed so far.
Methods and Results
Here we report a novel enzyme-free approach to efficiently detect cancer mutations. This
assay includes gene-specific target enrichment followed by annealing to oligonucleotides
containing locked nucleic acids (LNAs) and finally, detection by fluorescence microscopy.
The LNA containing probes display high binding affinity and specificity to DNA containing
mutations, which allows for the detection of mutation abundance with an intercalating Eva-
Green dye. We used a second probe, which increases the overall number of base pairs in
order to produce a higher fluorescence signal by incorporating more dye molecules. Indeed
we show here that using EvaGreen dye and LNA probes, genomic DNA containing BRAF
V600E mutation could be detected by fluorescence microscopy at low femtomolar concen-
trations. Notably, this was at least 1000-fold above the potential detection limit.
Conclusion
Overall, the novel assay we describe could become a new approach to rapid, reliable and
enzyme-free diagnostics of cancer or other associated DNA targets. Importantly,
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stoichiometry of wild type and mutant targets is conserved in our assay, which allows for an
accurate estimation of mutant abundance when the detection limit requirement is met.
Using fluorescence microscopy, this approach presents the opportunity to detect DNA at
single-molecule resolution and directly in the biological sample of choice.
Introduction
Single-nucleotide polymorphisms (SNPs) and variants (SNVs) are the main source of genetic
variation in human genome and other species [1]. Therefore, reliable detection of SNPs
and SNVs is an important clinical and translational research tool. Some of the many applica-
tions include drug-resistance analysis in viral genomes and cancer associated somatic DNA
alterations [2]. One human cancer gene in particular, BRAF or v-Raf murine sarcoma viral
oncogene homolog B, encodes the protein B-Raf [3]. More formally known as serine/threo-
nine-protein kinase B-Raf, this protein affects intracellular signalling and is involved in direct-
ing cell growth [3]. Mutations in BRAF have been implicated in some human cancers,
particularly melanoma [4]. Incidentally, several drugs have been developed that treat cancers
driven by BRAF, two of which, vemurafenib and dabrafenib, are now FDA approved for treat-
ment of late-stage melanoma [5,6]. Current detection methods of mutations in BRAF subjects
biopsy samples to PCR and/or sequencing. A less invasive approach detects BRAFmutations
directly in circulating tumor DNA (ctDNA) obtained from patient’s plasma [7]. However,
since ctDNA are present at very low concentrations (100–300 molecules per 100 μL analyte),
highly sensitive and specific detection techniques have to be applied [8].
Generally, development in the field of SNP/SNV diagnostics goes simultaneously in two
directions: 1) high-throughput methods, and 2) portable, easy-to-handle assays [8,9]. High-
throughput sequencing and polymerase-chain reaction (PCR) are current methods of choice
for research on cancer and infectious diseases in developed countries [9]. More available tech-
niques for rapid point-of-care diagnostics in the absence of sequencing and PCR are appealing.
Moreover, all high-throughput techniques developed to date apply enzymes in order to achieve
the required sensitivity and specificity of detection [9]. Enzymes increase the risk of errors dur-
ing the analysis and affects stoichiometry of the targeted mutation with respect to wild-type
analogue [10]. Thus, all methods of nucleic acids detection and quantification would benefit
from alternative enzyme-free strategies [9,10].
An ideal, easy-to-handle diagnostic of SNP/SNV is a simple robust assay with minimal
steps, high sensitivity and repeatability at low cost [9]. With these objectives in mind, a solid
support or in solution system using optical and electrochemical methods is ideal [11]. Fluores-
cence is a convenient optical detection method which is broadly applied in both modern state-
of-the-art and portable diagnostic assays [9]. In particular, recent developments in fluorescent
microscopy is having a huge impact on detection of biomolecules in vitro and in vivo [12,13].
Microscope techniques have made previously unachievable single-molecule detection available.
This provides an opportunity to avoid enzymes when detecting biomolecules in vitro and a
chance to monitor targets in vivo [9–13].
To detect SNP/SNVs at very low concentrations, highly specific and sensitive probes have to
be applied. One approach is to place locked nucleic acids (LNAs) with directly attached fluoro-
phores into short oligonucleotides [14]. These types of LNA/DNA capture probes are currently
applied in enzymatic genotyping of SNPs in a microarray format and PCR-based techniques
[15]. Recently we introduced fluorescently labelled LNA derivatives as a promising tool in
advanced genotyping, for example drug-resistance testing of highly polymorphic HIV-1 prote-
ase [16]. However, synthesis of fluorescently labelled probes is more expensive and labor-
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intensive than is necessary for point-of-care applications. A more straightforward probe design
could apply the highly efficient hybridization properties of LNA/DNA oligonucleotides in con-
junction with a robust, fluorescent intercalating dye such as EvaGreen. During the last decade
intercalating dyes have been successfully applied in enzymatic techniques on nucleic acid
detection [2–5]. In this paper we chose EvaGreen dye because of the demonstrated contrast
between the bright signal it gives off when bound to double-stranded DNA and the quenched
fluorescence signal with single-stranded samples [17].
Herein, we describe a new assay for rapid enzyme-free detection of BRAFV600E mutation
(T!A at gene position 1799) in human DNA (Fig 1). We initially enrich the target DNA using a
gene specific 120mer enrichment probe, followed by fluorescent detection with EvaGreen dye
and a second mutation specific, shorter LNA/DNA capture probe. By using serial dilutions of
mutant/wild-type cell line DNAmixtures, we demonstrate that this novel assay is highly potent
for the fluorescent sensing of a clinically relevant SNP at low concentrations and high sample
complexity. Furthermore we prove that by applying fluorescence microscopy we can specifically
detect low femtomolar and attomolar concentrations of DNA containing the target mutation.
Materials and Methods
General
Reagents obtained from commercial suppliers were used as directed. LNA Phosphoramidite
reagents and EvaGreen dye (20X in water) were obtained from Exiqon and Biotium,
Fig 1. Detection of cancer DNA using novel enzyme-free assay. The main steps of the LNA/DNA assay:
1) binding to gene-specific capture probe, 2) washing and cleavage from support, 3) adding signal-enhancing
LNA/DNA probe and intercalating dye, 4) fluorescence detection. B = biotin, S = streptavidin,
CPG = controlled pore glass, L = LNA.
doi:10.1371/journal.pone.0136720.g001
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respectively. Unmodified and biotinylated DNA strands were purchased from IDT and used
after HPLC purification.
Details on oligonucleotide synthesis, characterization and thermal denaturation studies are
given in S1 Appendix.
Genomic DNA
Genomic DNA from cell lines LS411N and HT29 were obtained directly from supplier (ATCC,
catalogue nr. CRL-2159 and HTB-38, respectively), and extracted using the Qiagen DNeasy tis-
sue culture extraction system per the manufacturer’s guidelines (Qiagen). HMC-1 (human
male control) was obtained from Promega [18]. The product was digested for 12 h at 37°C
using EcoRI (New England Biolabs), and precipitated from ethanol. Length of fragments was
measured using Agilent BioAnalyzer DNA 7500 kit giving a value of approx. 7000 bp.
Pre-enrichment of BRAF gene fragment. Pre-enrichment of genomic DNA was carried
out using xGen Lockdown kit (IDT), 120mer BRAF-specific probe labeled with biotin (IDT),
and streptavidin-coated magnetic beads (Dynabeads-M270, LifeTechnologies). The 120mer
probe was designed to overlap the BRAF V600E region (position of V600E mutation is
underlined):
5’-ACAACTGTTCAAACTGATGGGACCCACTCCATCGAGATTTCACTGTAGCTAGACCAA
AATCACCTATTTTACTGTGAGGTCTTCATGAAGAAATATATCTGAGGTGTAGTAAGTAAAGG-
(biotin-C6)-3’
Pre-digested genomic DNA and biotinylated 120mer probe were incubated for 5 h at 60°C
followed by attachment to magnetic beads, multiple washing steps and detachment by heat as
suggested by the supplier (IDT; heating to 92°C for 10 min). As a result, single stranded DNA
was obtained.
Solid-support hybridization assay. The DNA concentration was calculated using the
molecular weight and Life Technologies DNA copy number calculator available on their web-
site. Thus, 50 fM of ss DNA fragments (length 5000 nt) corresponded to 3x106 molecules per
100 μL, or 1x106 molecules of the same DNA fragment in the 100 μL of the sample corre-
sponded to the concentration 16.6 fM. Solid support containing corresponding capture probe
and target DNA (1 eq.) were placed into 1.5 mL Eppendorf tube containing 100 μL of 1X PBS
buffer. The resulting mixture was heated for 10 min at 85°C and subsequently cooled to room
temperature over 20 min. The support was centrifuged at 11.000 rpm for 10 min, and after
removing the supernate it was washed 2 times with 100 μL 1X PBS at 37°C. Afterwards Eva-
Green dye (0.06−0.6X) and the corresponding signal-enhancing probe (4 eq.) were hybridized
to the support (100 μL 1X PBS, 85°C, 10 min followed by cooling to RT over 20 min). Fluores-
cence signal was initially analyzed using standard laboratory UV-vis lamp. For analysis in solu-
tion and microscopy, the oligonucleotides were cleaved from support using 32% aqueous
ammonia and methylamine 1:1 (v/v) for 4 h at RT, evaporated and re-annealed in presence of
EvaGreen dye as described above (0.06−0.6X).
Fluorometry
DNA amounts (concentrations and number of molecules) were determined using standard
UV-spectrophotometry and Life Technologies DNA copy number calculator available as
described above. For the annealing, probes were heated for 10 min at 85°C and subsequently
cooled to room temperature over 20 min. Fluorometry studies of the resulting samples were
performed at 19°C in 1X PBS using PerkinElmer LS 55 luminescence spectrometer equipped
with a Peltier Temperature Programmer, excitation at 500 nm and recording emission at
530 nm.
Enzyme-Free Detection of DNAMutations
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Fluorescence microscopy
The multiphoton excitation fluorescence microscopymeasurements were completed on a cus-
tom built multiphoton excitation microscope [19]. Briefly, the objective used was a 60X water
immersion objective NA 1.29. The laser was a Ti:Sa laser (HPeMaiTai DeepSee, Spectra Phys-
ics, Mountain View, CA) and the excitation wavelength used was 840 nm. The fluorescence sig-
nals were collected using bandpass filters Bandpass 525/35 nm (AHF Analysentechnik AG,
Germany). The detectors were Hamamatsu H7422P-40 PMTs.
Results and Discussion
Initially, we designed capture probes of different length (9, 11 and 18mers) containing three
LNAs in central positions within the sequences (Table 1). According to our design, one of the
LNA units was complimentary to the potential BRAF V600E mutation (T!A) in the target
[16]. We investigated the uniqueness of each capture probe CP1-CP3 for hybridization to the
target region as compared to the entire 3 billion bp human genome using in house software
available at Stanford University (S1 Table) [20]. Thus, the 9mer and 11mer probes had multiple
binding sites in the genome, allowing zero, one or more mismatches, whereas the 18mer probes
(CP3) were completely specific to the target. As a negative control, we used an equivalent 9mer
DNA sequence applied in our previous assays that was not complimentary to the BRAF target
(capture probe CP4) [14].
Next, CP1−CP4 were prepared using automated solid-phase oligonucleotide synthesis on
controlled pore glass (CPG, Table 1). CP1−CP3 were synthesized as both wild-type (w) and
mutant (m) variants to BRAF 1790–1800 region (i.e. containing nucleotides A and T in the
position opposite to the base 1799, respectively). Capture probes were either detached from
CPG or kept on solid support after the synthesis (Supporting information). This allowed us to
perform the analysis both in solution and on solid support as described below.
We analysed the binding affinities of CP1−CP3 to fully complementary and mismatched 63
nt BRAF fragments in solution (Tm values, Table 1). As expected, internally positioned LNAs
increased the melting temperatures of all the probes by 3.0–4.5°C per one LNA incorporation.
Table 1. Sequences and thermal denaturation temperatures of LNA/DNA capture probes prepared in
this study.a
Capture probe # Sequence, 50!30 Tm, °C—T1 (Wt) Tm, °C–T2 (Mut)
CP1w TT+T C+A+C TGT 34.5 22.0
CP2w GAT T+TC +A+CT GT 43.0 33.5
CP3w GAG ATT +TC+A +CTG TAG CTA 56.5 46.0
CP1m TT+T C+T+C TGT 35.0 23.0
CP2m GAT T+TC+T +CT GT 44.0 34.5
CP3m GAG ATT +TC+T +C TG TTA 55.0 46.5
CP4 GTG ATA TGC - -
a Thermal denaturation temperatures Tm (°C)/change in Tm relative to corresponding reference duplex, ΔTm
(°C). Tm values measured as the maximum of the ﬁrst derivatives of the melting curves (A260 vs
temperature). Reported Tm values were obtained in medium salt buffer and are averages of at least two
measurements with resulting Tm ± 0.5°C. LNA nucleotides are marked with plus before the corresponding
letter. Allele-speciﬁc nucleotide is underlined. 63Mer BRAF target sequences (SNP position is underlined):
5’-CATGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGC TACAGTGAAATCTCGATGGAGT-3’
(T1); 5’-CATGAAGACCTCACAGTAAAAATAGGTGATT TTGGTCTAGCTACAGAGAAATCTCGATGGAGT-
3’ (T2).
doi:10.1371/journal.pone.0136720.t001
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Simultaneously target specificity was increased, because the Tm decreased by 10.0–11.0°C in
the presence of a mismatch. No duplexes were formed at temperatures above 22°C for the
9mer capture probes CP1w,m. This suggests that CP1w,m probes have the highest potential to
discriminate a mismatched vs. fully-matched targets. However this might be accompanied by a
lack of specificity within the human genome as suggested by our probe uniqueness analysis
(Supporting information). In turn, the 18mer capture probes showed high Tm values for both
fully-matched and mismatched duplexes and the 11mer CP2w and CP2m had somewhat inter-
mediate values (33.5°C–34.5°C in the presence of a mismatch). Finally, negative control CP4
showed no binding to the target sequences.
Having studied hybridization properties of LNA/DNA capture probes, we applied them to
the detection of the BRAF V600E mutation in human genomic DNA (Figs 2 and 3, Table 2).
We determined, using digital PCR (data not shown), that the human cell lines HT29 and
LS411N had a 25.0% and 66.7% abundance of the target mutation, respectively [18]. HMC-1
DNA was used as a 100% wild-type control as it possessed no mutation. First, we pre-enriched
the DNA using a 120mer BRAF specific probe labeled with streptavidin that did not overlap
the region of the capture probe and thus was universal for both the wt and mut targets (Fig 1
and Materials and Methods;). This step increased concentration of the target genome fragment
and simultaneously improved specificity of our assay in the same way as when being applied
prior to next-generation sequencing [7–8]. After multiple washing steps and detachment from
the biotinylated magnetic beads, single-stranded BRAF fragments (7000 nt) were recovered
into the solution.
Afterwards, pre-enriched BRAF targets were annealed to the capture probes CP1–CP4
directly on solid support [11]. We then used EvaGreen to detect and quantify the double-
stranded DNA. EvaGreen signal increases proportionally to the number of base pairs in the
formed duplex [17]. That being said, the capture probe:target complex was rather short (9–18
base pairs). In order to avoid a weak signal we applied an additional LNA/DNA signal-enhanc-
ing probe complementary to the sequence just adjacent to the capture probe (P1; 50 nt). This
probe showed no self-folding properties and bound both wild-type and mutant targets
Fig 2. Main principle of DNA detection by short LNA/DNA capture probes on solid support. Target
binding specificity results from the difference in melting temperature (Tm) between fully-matched and
mismatched capture probe:target complexes. CPG = controlled pore glass.
doi:10.1371/journal.pone.0136720.g002
Enzyme-Free Detection of DNAMutations
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universally (Fig 2 and S1 Appendix). Longer signal-enhancing probe would result in even
higher signal increase upon target binding. However, LNA/DNA probes of length> 50 nt are
challenging to synthesize and purify. Moreover, their target binding properties have to be addi-
tionally evaluated to avoid false positive signal due to e.g. self-folding (paper in preparation).
Furthermore, with the solid-support system we were able to take advantage of the Tm differ-
ence between fully matched and mismatched target:probe pairs (Table 1). A simple washing
step at the Tm of the mismatched complex allowed us to eliminate binding of the mismatched
Fig 3. Detection of cancer DNA by fluorescence. (A) Visualization of BRAF V600Emutation on solid-
support containing capture probeCP2m: CP2m:HT29 (2.5 pM, tube 1), CP2m:LS411N (2.5 pM, tube 6).
Signal is obtained under laboratory UV-vis lamp (excitation at 365 nm) at 19°C using 10 pM signal-enhancing
probe and 0.6X EvaGreen dye. (B) Quantification of genomic BRAF targets by fluorometry in solution. Target
titration curves were obtained for fully complementary and mismatched complexes (blue and red lines,
respectively) of LNA/DNA capture probes CP2w andCP2mwith corresponding targets and signal-enhancing
probe P1: 5’-GCT A+GA CCA +AAA TCA CCT A+TT TTT ACT GTG AG+G TCT TCA TGA AGA +AAT AT-3’.
LNA nucleotides are marked with plus before the corresponding letter.
doi:10.1371/journal.pone.0136720.g003
Table 2. Quantification of BRAF V600Emutation in cancer cell line DNA using fluorometry.a
Cell line DNA concentration (wt+mut), fM I (500/530)–
background*
Estimated number
of BRAF
molecules (copy
number) per
100 μL, ×107
Abundance of mutant
CP2w CP2m Wt Mut sequence, %*
HT29 250 110 23 1.2 0.3 17.3
50 24 5 0.2 <0.1 17.2
LS411N 250 49 101 0.5 1.0 67.2
50 10 21 <0.1 0.1 67.7
HMC-1 250 145 - 1.5 0.0 0.0
50 28 - 0.3 0.0 0.0
a For details of the BRAF copy number calculation, see Materials and Methods. Thus, 50 fM ss DNA corresponds to 3x106 molecules per 100 μL, or 1x106
molecules of genomic DNA in 100 μL of the sample corresponds to the concentration 16.6 fM. Abundance value is determined using ratio of EvaGreen
ﬂuorescence obtained for individual analysis on wild-type and mutant speciﬁc capture probes as follows: I(CP2m)/(I(CP2m)+I(CP2w)).
* I (excitation/emission wavelength, nm); background signal is determined by ﬂuorescence measurement of free single-stranded genomic DNA at the
same concentration.
doi:10.1371/journal.pone.0136720.t002
Enzyme-Free Detection of DNAMutations
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sequence. Finally, the sample was re-annealed in the presence of signal-enhancing probe P1
and EvaGreen dye (Figs 1 and 2).
The solid support containing cancer DNA:probe complex was visualized using a standard
laboratory UV lamp (Fig 3 and S2 Table). When the mutant-specific capture probe was
applied, the presence of the mutant target could be clearly detected with the naked eye. For fur-
ther quantification, the sample was detached from CPG, re-annealed and subjected to analysis
by fluorometry (Fig 3). We estimated the concentrations of the wild-type and mutant targets in
the cancer DNA by using a titration curve. This was generated with a fluorometry assay in solu-
tion using a known initial amount of genomic DNA in analyte (in mol and number of mole-
cules), and the same concentrations of reagents as in the experimental assay (see Materials and
Methods). Limit of detection (LOD) has been calculated as the lowest target concentration
which could be detected with a signal to noise ratio above 3 [14]. Thus, we established LOD
value of 50 fM genomic DNA using conventional fluorometry (Table 2; see Materials and
Methods for details on the calculation).
When comparing results between capture probes CP1−CP3, the 11mer CP2 showed the
highest discrimination of mismatched targets while maintaining good binding specificity (Fig
3). In contrast, the longer CP3 probes showed similar signal for fully matched and mismatched
complexes, since the duplex was still formed at the temperature of the assay (Table 1 and S1
Fig). Using CP2m, we also achieved high accuracy for the abundance quantification of the cell
line LS411N (67.2%–67.7% determined by our assay vs. 66.7% determined by digital PCR).
However, the lower mutant abundance in the HT29 DNA was detected with our assay at a
higher error level compared to LS411N (deviation of* 8% vs. 1%, respectively). Most likely,
this was caused by the emission signal of the mutant target in HT29 being below our reliable
LOD.
The specificity of detection was confirmed by the absence of fluorescence signal when using
CP2m and wild-type control DNA, HMC-1 (Table 2). Notably, the pre-enrichment step dra-
matically increased the concentration of BRAF fragment in the sample. This was confirmed by
up to 10-times elevated non-specific signal upon detection of non-enriched HMC-1 DNA with
the CP2m probe (data not shown). Therefore, we concluded that both the pre-enrichment step
and the design of the mutation probe were essential for the assay. We estimated the accuracy of
targeting a specific BRAF region to be within ±1%. Taking into account the large sequence
complexity of human genomic DNA, we concluded that the accuracy of our BRAF gene target-
ing using LNA/DNA probes was very good [10,21].
As a final aspect, we subjected a series of highly diluted HT29 mutant DNA molecules to
detection by fluorescence microscopy (Fig 4). Prior to analysis, we pre-enriched the target
DNA, annealed it to CP2m on a solid support (CPG) and afterwards cleaved it from the CPG
as described above. With this method the complex of BRAF target, CP2m, P1 and EvaGreen
dye could be easily detected at* 1.5 fM concentration of mutant DNA corresponding
to* 1×105 molecules per 100 μL analyte (for details on calculation, see Materials and Meth-
ods). The DNA:EvaGreen complex was seen to form small aggregates on the cover glass surface
of approx. 1μm in diameter. In the absence of P1, the fluorescence signal was four times dim-
mer and no fluorescence was observed for the EvaGreen dye control (Fig 4 and S2 Fig). More-
over, no signal was observed using the 100% wild-type control DNA HMC-1 in the same
setting. To the best of our knowledge, these LOD values have only been previously reported for
PCR-based assays but not any amplification-free methods. Moreover, the observed signal
could be detected at 1000-times lower concentrations of DNA than even 1.5 fM corresponding
to only 100 molecules per 100 μL analyte. We speculate that by applying this technique and
increasing the length of the signal-enhancing probe as mentioned above, the LOD value for
cancer DNA could be far below 1 aM.
Enzyme-Free Detection of DNAMutations
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Comparing our method to previously reported genotyping methods for BRAFmutation and
other sequence variations, the developed assay is beneficially low in cost, time (12 hours vs. up
to 1 week) and robustness [9,14]. Importantly, no enzymes, besides restriction enzymes for the
fragmentation genomic DNA, are needed for the detection of the target mutation [22–24]. This
prevents errors which often occur with PCR or alignment of sequencing data [3,11]. Stoichi-
ometry of wild type and mutant targets is also conserved in our assay, which allows for an accu-
rate estimation of mutant abundance, given that the limit of target detection requirement is
met. In previously reported assays this could be achieved using gold nanoparticles, DNAzymes
or electrical detection [25–27]. In this work we improve upon the sensitivity of target detection
by applying signal-enhancing probes and laser microscopy, which presents the opportunity to
detect sequence variations in target DNA at low concentrations directly in human serum [28].
In summary we describe a novel assay which allows for the rapid analysis of cancer muta-
tions. To achieve necessary specificity and sensitivity of target detection, the assay combines
several principles: 1) target pre-enrichment using a long, gene-specific probe (120mer); 2) high
binding affinity and specificity of short LNA probes, and 3) DNA detection by high resolution
fluorescence microscopy. As we prove in this work, the combination of these techniques
enables rapid analysis of mutations in cancer DNA without the need for amplification or other
enzymatic reactions. Successfully demonstrated as a proof-of-principle on the V600E mutation
in the BRAF oncogene, this method can be applied to detect other mutations of clinical signifi-
cance (e.g. codons 12 and 13 of KRAS gene [29]) and serve as a simple, reliable method for
research, prognostic or therapy monitoring of clinical samples.
Fig 4. Fluorescence images ofBRAF DNA fragments from cell line HT29. (A) Complex of DNA with CP2m, signal-enhancing probe P1 and EvaGreen
dye, bright dots with intensities over 80 are seen. (B) Target DNA re-annealed with CP2m and EvaGreen dye in the absence of P1, darker dots are seen with
counts up to about 20. (C) EvaGreen dye in 1xX PBS (0.06X solution), no signal is seen. Images were obtained using two photon laser scanning microscope
(ex 535+35nm; laser@ 840); at 19°C using 1.5 fM cancer DNA and re-annealing with 10 pM signal-enhancing probe and 0.06X EvaGreen dye. The images
were taken using the same instrument settings and adjusted using the same intensity threshold. The graph below the images shows a line plot of the line in
the image.
doi:10.1371/journal.pone.0136720.g004
Enzyme-Free Detection of DNAMutations
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Supporting Information
S1 Appendix. Oligonucleotide synthesis, characterization and thermal denaturation stud-
ies.
(DOCX)
S1 Fig. Visualization of cancer DNA on solid-support containing capture probe CP3m.
(Left to right) tubes 1–3: CP3m:HT29 (10.0, 5.0 and 2.5 pM), tubes 3–6: CP3m:LS411N (10.0,
5.0 and 2.5 pM). Signal is obtained under laboratory UV-vis lamp (excitation at 365 nm), at
19°C using 10 pM signal-enhancing probe and 0.6X EvaGreen dye.
(TIF)
S2 Fig. Fluorescence images of BRAFDNA fragments from cell line HT29. (A) Complex of
DNA with CP2m, signal-enhancing probe P1 and EvaGreen dye, bright dots with intensities
over 80 are seen. (B) Target DNA re-annealed with CP2m and EvaGreen dye in the absence of
P1, darker dots are seen with counts up to about 20. (C) EvaGreen dye in 1X PBS (0.06X solu-
tion), no signal is seen. (D) Wild-type control DNA HMC-1, no signal is seen.
(TIF)
S1 Table. Uniqueness analysis of capture and signal-enhancing probes.
(PDF)
S2 Table. Colorimetric analysis of model targets and genomic DNA on solid support.
(PDF)
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